|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM257488847 |
| 003 |
DE-627 |
| 005 |
20250219173321.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20160126-08
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0858.xml
|
| 035 |
|
|
|a (DE-627)NLM257488847
|
| 035 |
|
|
|a (NLM)26878448
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Seth, Anisha
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Intravitreal Diclofenac in the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.11.2016
|
| 500 |
|
|
|a Date Revised 30.12.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2016, SLACK Incorporated.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: To evaluate the effect of a single dose of intravitreal diclofenac on macular edema (ME) due to branch retinal vein occlusion (BRVO)
|
| 520 |
|
|
|a PATIENTS AND METHODS: In this prospective, interventional case series, 15 eyes with BRVO and ME with central macular thickness (CMT) greater than 250 µm on spectral-domain optical coherence tomography (SD-OCT) were enrolled. All patients were given 0.05 mg/0.1 mL of intravitreal diclofenac under aseptic conditions and followed up for 3 months with respect to best-corrected visual acuity (BCVA), intraocular pressure (IOP), fundus fluorescein angiography, and CMT measured on OCT
|
| 520 |
|
|
|a RESULTS: The mean visual acuity improved from 0.115 ± 0.03 preoperatively to 0.356 ± 0.29 at 3 months (P = .002). Mean line improvement was 2.2 ± 1.6. Mean preoperative CMT decreased from 453.2 µm ± 55.3 µm to 340.47 µm ± 101 µm at 3 months postoperatively (P = .001). The mean preoperative IOP was 16.4 mm Hg ± 1.59 mm Hg, whereas the mean postoperative IOP was 16.6 mm Hg ± 1.58 mm Hg (P = .08). None of the 12 phakic eyes showed evidence of cataract progression
|
| 520 |
|
|
|a CONCLUSION: Intravitreal diclofenac is safe and effective in improving BCVA and decreasing CMT in patients with BRVO and ME
|
| 650 |
|
4 |
|a Clinical Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents, Non-Steroidal
|2 NLM
|
| 650 |
|
7 |
|a Ophthalmic Solutions
|2 NLM
|
| 650 |
|
7 |
|a Diclofenac
|2 NLM
|
| 650 |
|
7 |
|a 144O8QL0L1
|2 NLM
|
| 700 |
1 |
|
|a Ghosh, Basudeb
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Raina, Usha K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gupta, Anika
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arora, Supriya
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 47(2016), 2 vom: 11. Feb., Seite 149-55
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnns
|
| 773 |
1 |
8 |
|g volume:47
|g year:2016
|g number:2
|g day:11
|g month:02
|g pages:149-55
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20160126-08
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 47
|j 2016
|e 2
|b 11
|c 02
|h 149-55
|